Tempus AI posts 22% revenue growth, eyes $1.6bn by 2026 with Big Pharma deals and MRD cancer testing expansion

Tempus AI reported a strong 22% year-over-year revenue growth and projects revenues to reach $1.6 billion by 2026, driven by its AI-powered diagnostics and data licensing model. The company recently went public in June 2024, raising $411 million, and its stock price has surged to $65 per share, valuing the company at $12.23 billion. Strategic partnerships with major pharmaceutical companies and the acquisition of Personalis position Tempus AI to benefit from the growing minimal residual disease (MRD) cancer testing market. Upcoming FDA approvals and pipeline developments could add $400 million in revenue by 2028, supporting sustained growth and a premium valuation.

Following Tempus AI's recent public debut and growth announcements, its shares are trading at USD 63.39 on Pluang as of Oct 23, 2026 19:41 WIB, down 0.66% for the day with a market cap of $11.63 billion. The stock remains well above its 52-week low of $41.55 but below its 52-week high of $91.58. Personalis, recently acquired by Tempus AI, is priced at USD 15.80, down 0.13% on the day, reflecting steady investor interest with a typical hold time of 8 days on Pluang.